| 1.62 0.01 (0.62%) | 03-17 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 2.09 | 1-year : | 2.44 |
| Resists | First : | 1.78 | Second : | 2.09 |
| Pivot price | 1.62 |
|||
| Supports | First : | 1.44 |
Second : | 1.23 |
| MAs | MA(5) : | 1.67 |
MA(20) : | 1.58 |
| MA(100) : | 1.38 |
MA(250) : | 1.1 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 59.4 |
D(3) : | 69.2 |
| RSI | RSI(14): 56.1 |
|||
| 52-week | High : | 1.83 | Low : | 0.31 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ LXRX ] has closed above bottom band by 49.6%. Bollinger Bands are 15.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.67 - 1.68 | 1.68 - 1.69 |
| Low: | 1.56 - 1.57 | 1.57 - 1.58 |
| Close: | 1.6 - 1.62 | 1.62 - 1.64 |
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Wed, 18 Mar 2026
Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Price Crosses Above Two Hundred Day Moving Average - Here's What Happened - MarketBeat
Mon, 16 Mar 2026
Lexicon Pharmaceuticals (LXRX) 2025 10-K: pipeline updates, collaborations - Stock Titan
Mon, 16 Mar 2026
Lexicon Pharmaceuticals (NASDAQ: LXRX) asks holders to double shares, renew equity plans - Stock Titan
Thu, 12 Mar 2026
H.C. Wainwright Raises its Price Target on Lexicon Pharmaceuticals, Inc. (LXRX) to $6 from $4 and Maintains a Buy Rating - Yahoo Finance
Tue, 10 Mar 2026
Citigroup Raises Price Target for Lexicon Pharmaceuticals (LXRX) - GuruFocus
Sun, 08 Mar 2026
Lexicon Pharmaceuticals, Inc. 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:LXRX) 2026-03-08 - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 418 (M) |
| Shares Float | 358 (M) |
| Held by Insiders | 1 (%) |
| Held by Institutions | 66.4 (%) |
| Shares Short | 24,520 (K) |
| Shares Short P.Month | 25,160 (K) |
| EPS | -0.19 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.33 |
| Profit Margin | -96.8 % |
| Operating Margin | -86 % |
| Return on Assets (ttm) | -13 % |
| Return on Equity (ttm) | -46 % |
| Qtrly Rev. Growth | 710.4 % |
| Gross Profit (p.s.) | -0.02 |
| Sales Per Share | 0.16 |
| EBITDA (p.s.) | -0.13 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -72 (M) |
| Levered Free Cash Flow | -38 (M) |
| PE Ratio | -8.53 |
| PEG Ratio | 0 |
| Price to Book value | 4.9 |
| Price to Sales | 9.55 |
| Price to Cash Flow | -9.39 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|